Advertisement
Advertisement
FULC
Fulcrum Therapeutics, Inc. Common Stock
7.04
USDSponsored
+0.11
+1.60%
Mar 19, 15:59 UTC -4
Closed
Pre-Market
6.94
-0.10
-1.43%
FULC Earnings Reports
Positive Surprise Ratio
FULC beat 20 of 27 last estimates.
74%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.30
Implied change from Q4 25 (Revenue/ EPS)
--
/-3.23%
Implied change from Q1 25 (Revenue/ EPS)
--
/+7.14%
Fulcrum Therapeutics, Inc. Common Stock earnings per share and revenue
On Feb 24, 2026, FULC reported earnings of -0.31 USD per share (EPS) for Q4 25, beating the estimate of -0.31 USD, resulting in a 1.68% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -21.21% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 9 analysts forecast an EPS of -0.30 USD, with revenue projected to reach -- USD, implying an decrease of -3.23% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Mar 18, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.37
Surprise
-706.10%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
$0.09
Actual
$0.05
Surprise
-45.53%
Cellectis S.A. - ADR
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.26
Surprise
+1.78%
XOMA Royalty Corporation Common Stock
Report Date
Mar 18, 2026 For Q4 25
Estimate
-$0.15
Actual
$0.12
Surprise
+175.90%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Mar 18, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.07
Surprise
-1472.55%
Eledon Pharmaceuticals, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.20
Actual
-$0.10
Surprise
+51.78%
Artiva Biotherapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.84
Actual
-Surprise
-
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
Pelthos Therapeutics Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$4.21
Actual
-$2.83
Surprise
+32.82%
FAQ
What were Fulcrum Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Fulcrum Therapeutics, Inc. Common Stock reported EPS of -$0.31, beating estimates by 1.68%, and revenue of $0.00, 0% as expectations.
How did the market react to Fulcrum Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -21.21%, changed from $10.89 before the earnings release to $8.58 the day after.
When is Fulcrum Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for Fulcrum Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analysts, Fulcrum Therapeutics, Inc. Common Stock is expected to report EPS of -$0.30 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement